Ocean-derived carbohydrates are making waves in drug development

The sea is more than a source of seafood — it could be a goldmine for medicine. A comprehensive review published in Glycoscience & Therapy explores how carbohydrates from marine organisms like algae, sea animals, and microorganisms possess unique structural features — unusual sulfate patterns, sugar linkages, and branched architectures — that give them powerful biological properties, including antiviral, anticoagulant, immunomodulatory, and antitumor activity.

The review traces the clinical journey of marine carbohydrates from cytarabine, a marine-inspired leukemia drug approved in the U.S. in 1969, through to current clinical-stage candidates being tested for viral infections, cancer, metabolic disorders, cystic fibrosis, tissue repair, and neurological disease. A key challenge: turning complex natural carbohydrates into reproducible, safe medicines, since factors like molecular weight, sulfation patterns, and extraction methods can all affect how a compound behaves.

Key Takeaways:

• Reliable production methods — via cultivation, fermentation, or enzymatic processing — are critical for scalability
• Rigorous quality control and pharmacokinetic studies are needed before broader clinical use
• Progress will require cross-disciplinary collaboration across glycoscience, synthetic biology, and clinical research

Why it matters: Marine carbohydrates represent an underexplored frontier in drug development. As researchers refine production and quality standards, these ocean-derived compounds could expand treatment options across multiple disease areas.